In Q1 2025, 3 billion rubles’ worth of botulinum toxin products (retail prices, VAT included) was sold in Russia, according to RNC Pharma’s Audit of Aesthetic Injectable Retail Sales database. The sales went up 36.9% from January–March 2024. In physical terms, 33.3 million units of botulinum toxin were sold, up 29.4% from Q1 2024. In 2024, the sales were 131 million units worth 11.2 billion rubles, up 12.5% in physical and 23% in monetary terms from 2023.

For aesthetic injectables, seasonality is particularly prominent, leading to sales peaking in May and December. In May 2024, 13.3 million units of botox worth 1.11 billion rubles were sold, up 13.2% in physical and 20.6% in monetary terms from May 2023. In December 2024, it was 1.31 billion rubles, up 36.9% from December 2023 and 18.2% from May 2024. In physical terms, it was 15.2 million units, up 27.9% from December 2023.

The lowest sales of botox products were seen in January for three years in a row. In January 2025, only 9.4 million units worth 836 million rubles were sold, up 28.6% in physical and 36.3% in monetary terms from January 2024, when it was 7.3 million units worth 613.3 million rubles. Sales also tend to slow down in the summer, usually in July and August.

Aesthetic injectables are mainly sold in specialized institutions—aesthetic clinics. In Q1 2025, aesthetic clinics accounted for around 73% of the sales in physical terms. The average price of one unit of botox in clinics was 101.9 rubles (drug administration fee included). Since it does not include the drug administration fee, the price in pharmacies was significantly lower, 59 rubles per unit.

Dysport by Ipsen (France) was the best-selling drug in both monetary and physical terms, accounting for over 42% of the sales in rubles and for about 62.5% in units. The Russian products Relatox (Natsimbio) and Myotox (Innofarm) ranked second and third, together accounting for 46.4% of the sales in rubles and for 32% in units. The sales of Relatox and Myotox went up 46% and 63% in monetary terms, respectively, contributing to the growth rates of the market the most. Novacutan-BTA by Huons Global (South Korea) had the best growth rates of 78%, accounting for only 1.6% of the sales in monetary terms.